Abbott Laboratories ConfidentialPage 1 Update on West Nile Virus George J. Dawson, Ph.D. Abbott Laboratories.

Slides:



Advertisements
Similar presentations
Nick Curry, MD, MPH Infectious Diseases Prevention Section
Advertisements

Development of a Panel for Dengue Virus Maria Rios, PhD CBER/FDA Blood Products Advisory Committee Meeting December 14, 2010.
HIV-1/HIV-2 PLUS O To detect HIV Antibody Groups M & O Genetic Systems™ HIV-1/HIV-2 PLUS O EIA   HIV Subtypes and Variants   Description of HIV-1/HIV-2.
Supplemental Testing of Donors for HIV and HCV September 18, 2003 BPAC Meeting Robin Biswas, M.D. Indira Hewlett, Ph.D. FDA/CBER/OBRR/DETTD.
Blood Products Advisory Committee Meeting Harold S. Gaithersburg, MD December 14, 2010 Harold S. Margolis, MD Chief, Dengue Branch Centers for Disease.
6/03/031 Hepatitis C –Update Laboratory Issues Hema Kapoor MD. SM Virology Section Manager Bureau of Laboratories Michigan Department of Community Health.
An Introduction to HIV Incidence Surveillance (HIS) in California California Department of Public Health Office of AIDS.
Use of avidity reagent. Panbio Buffered Avidity Reagent Mild protein-denaturing solution that may be useful in differentiating recent infections from.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Primary HIV Infection: the CDC study Pragna Patel, MD MPH Medical Epidemiologist Behavioral and Clinical Surveillance Branch DHAP, CDC February 28, 2005.
WNV Human Case Investigation and Reporting Kimberly Signs, DVM Michigan Department of Community Health.
Algorithms and Testing Results for West Nile/Arbovirus Testing (2002) used at Michigan Department of Community Health H. Kapoor, P. Clark, F. P. Downes,
Update on West Nile virus and Blood Safety November 3, 2005 Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.
Vironostika® HIV-1 Plus O Microelisa System
DIAGNOSIS OF WEST NILE VIRUS INFECTION IN ANIMALS Jon S. Patterson, DVM, PhD, DACVP Roger K. Maes, DVM, PhD Diagnostic Center for Population and Animal.
Testing algorithms used at Bureau of Labs Michigan Department of Community Health Information on testing algorithms for processing and reporting serological.
Dengue Virus and Its Risk to the U.S. Blood Supply
HIV Testing CDC power point edited by M. Myers
Laboratory Investigation
HIV Rapid Testing Dr. Kevin Harvey National HIV/AIDS Programme Ministry of Health Jamaica.
HIV Testing Quality Assurance and Quality Control
Lab-3 By: Dr.Malak El-Hazmi Assistant Professor & Consultant Virologist College of Medicine & KKUH.
E992750C 1 Replacement of HIV-1 p24 Antigen Screening with HIV-1 RNA Nucleic Acid Testing (NAT) for Whole Blood Donations S.L. Stramer, R.A. Porter, J.P.
Limitations of HBsAg testing in the screening of blood donors Wolfram H. Gerlich Institute of Medical Virology University Giessen, Germany SoGAT XVI Langen.
FDA Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components.
Reentry for Donors Deferred Based on Anti-HBc Test Results November 3, 2005 BPAC Meeting FDA/CBER/OBRR/DETTD.
SOLID PHASE IMMUNOASSAYS: INTERPRETING PATTERNS Julie Houp, CHS Johns Hopkins University School of Medicine Division of Immunogenetics and Transplantation.
Transmissibility of B19 by transfusion: evaluation of donor viremia prior to performing a linked donor-recipient study M Busch, representing REDS-II Parvo.
REAL-TIME SCREENING FOR WEST NILE VIRUS (WNV) OF ORGAN DONORS Claudia Chinchilla, CLSpMB 1, Jaime Siriban, CLS 1, Dem Brucal, CLS 1, James Schellenberg,
Panbio’s new JE-Dengue IgM Combo ELISA
Hema Kapoor MD. SM (NRM) Virology Section manager Bureau of laboratories Michigan Department of community Health Lansing Michigan Laboratory Issues and.
Maria Rios, Ph.D. CBER/FDA Blood Products Advisory Committee May 1st, WNV Epidemiology & FDA’s Recommendations on the Use of NAT to Reduce the.
Laboratory Issues and West Nile Virus Hema Kapoor MD. SM (NRM)
DIAGNOSIS OF HIV INFECTION THE LABORATORY BY DR. K.BUJJIBABU.MD.
E A 1 Parvovirus B19 and HAV Screening of Whole Blood Donations SL Stramer, KL Kane, ML Beyers, RY Dodd, American Red Cross and RIF Smith, National.
Theresa L. Smith, MD, MPH Division of Vector-Borne Infectious Diseases Centers for Disease Control and Prevention Fort Collins, CO West Nile Virus Epidemiology.
Retrospective and Prospective U.S. Donor MRV Surveillance and Transmission Studies Michael Busch, MD, PhD Blood Systems Research Institute Dept of Laboratory.
Update on Assay Development George J. Dawson, Ph.D. Infectious Diseases: Core R & D Abbott Laboratories West Nile Virus.
Approval Criteria for Assays for Testing Blood Donors for West Nile Virus Robin Biswas, M.D. CBER, FDA Blood Products Advisory Committee Meeting March.
Panbio Dengue ELISAs.
Qualification Panels for West Nile Virus RNA Tests Mark Manak, Ph.D. Boston Biomedica, Inc. West Bridgewater, MA SoGAT Langen, Germany July 3, 2003.
HIV diagnosis (general) ImmunoassaysNAT (PCR)
Overview of Data on Blood Donor Testing and Plan for Studies to Characterize Rates and Consequences of Transfusion Transmission of Dengue Virus Michael.
1 Blood Systems Trypanosoma cruzi and Chagas Disease Studies and Potential Strategies for Targeted Testing of Donors Blood Products Advisory Committee.
1 Procleix ® WNV Assay: A TMA-based Assay for Screening Blood Donations for West Nile Virus RNA Jeff Linnen, Ph.D. Research and Development Gen-Probe Incorporated,
Current Status of Issues Related to West Nile virus testing and donor screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.
Progress in West Nile virus Testing and Donor Screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.
West Nile Virus: Pathogenesis and Diagnostic Tools Maria Rios, PhD - Senior Staff Fellow Laboratory of Molecular Virology DETTD/OBRR/CBER/FDA WNV epidemic.
E001372A 1 ARC Experience with Indeterminate Blood Donors Susan L. Stramer, Ph.D. National Confirmatory Testing Laboratory American Red Cross.
E A 1 Supplemental Testing for HIV-1 and HCV Blood Products Advisory Committee Meeting September 18, 2003 Susan L. Stramer, Ph.D. National Testing.
The Enzyme Linked Immunosorbent Assay (ELISA).. Capture ELISAs Antigen Capture: In this, more specific approach, a capturing Ab is adsorbed onto the solid.
Development of Standard Reagents for WNV NAT M. Rios, A. Grinev, K. Sirnivasan, O. Wood, S. Daniel, I. Hewlett CBER/FDA.
SoGAT 2005 Donor screening for parvovirus B19 antibodies: Reducing or eliminating the risk of transmission SoGAT 2005 Gordon Elliott Biotrin 93 The Rise.
Test 1Test 2Test 3Test 4Test 5Test 6 Sensitivity Specificity PPV NPV Performance.
Validation of Nucleic Acid and Serological Tests to Screen Blood and Plasma donors for Acute infection with West Nile virus Hira Nakhasi, Ph.D. Director,
Blood Products Advisory Committee Meeting April 26, 2007 Ben Marchlewicz, Ph.D. PRISM R&D, Program Manager.
Recent Serologic Studies with Potential Impact on WNV Blood Screening Wayne Hogrefe, Harry Prince Focus Technologies.
CBER Update on status of West Nile virus test, lot release and validation panel development Indira Hewlett, Ph.D CBER/FDA Blood Products Advisory Committee.
Holland Laboratory David A. Leiby, PhD Transmissible Diseases Department American Red Cross Holland Laboratory and Department of Microbiology and Tropical.
Dengue fever caused by dengue virus (DENV), a member of Flaviviridae leads to large global disease burden. Detection of immunoglobulin M (IgM) and nucleic.
فيروس زيكا Zika Virus Prof. Dr. Abdelraouf A. Elmanama
RESULTS Division of Arboviruses, Center for Immunology and Pathology, National Institute of Health, Korea Centers for disease control, Osong, Korea BACKGROUND.
1 Special eSHARE Webinar: Overview of ELR vocabulary associated with Zika, dengue, and chikungunya viruses New Conference Number: Participant.
CBER Current Considerations for Blood Donor Screening for West Nile Virus Pradip N. Akolkar, Ph.D. Maria Rios, Ph.D. DETTD, OBRR Blood Products Advisory.
Incorporation of NAT into supplemental testing of HCV and HIV seroreactive donors Michael P. Busch representing Blood Systems Research Institute Blood.
Diagnostic Testing for Zika Virus Frederick S. Nolte, PhD, D(ABMM), F(AAM) Professor and Vice-Chair for Laboratory Medicine Department of Pathology and.
Zika Virus in Pregnancy
Update on CBER HIV-1 Subtype panel
ImmunoWELL Zika Virus Serology.
Challenges for Blood Donor Confirmatory Testing Algorithms
Presentation transcript:

Abbott Laboratories ConfidentialPage 1 Update on West Nile Virus George J. Dawson, Ph.D. Abbott Laboratories

Confidential Page 2 West Nile Virus Update Abbott’s commitment to WNV Abbott’s commitment to WNV will continue as needed to aid in understanding evolution of markers associated with infection Abbott’s Research WNV IgM assay : Abbott’s Research WNV IgM assay : Cutoff set based on human population studies, experimental infection studies in primates Repeatably reactive specimens were characterized with other serologic assays to confirm reactivity Supplemental tests from various sources have been utilized to aid in setting cutoff for Abbott’s test

Abbott Laboratories Confidential Page 3 West Nile Virus Update Recent observations indicate: Recent observations indicate: Considerable overlap of WNV RNA detection and IgM detection in the early stage of infection Low level viremics may be negative by minipool NAT and reactive by WNV IgM Infectivity studies may be required to determine transmissibility of low level viremic specimens More sensitive IgM assays have greater overlap with WNV RNA detection than less sensitive assays As WNV IgM tests become more sensitive, there are fewer options for confirmatory tests with appropriate sensitivity

Abbott Laboratories Confidential Page 4 West Nile Virus Specificity issues with WNV IgM assays for WNV Specificity issues with WNV IgM assays for WNV:. Cross reactivity 1. Cross reactivity A repeatably reactive test result may be induced by flaviviruses other than WNV due to relatively high degree of amino acid homology between proteins of WNV and other flaviviruses 2. Confirmatory testing Low level reactives may be difficult to confirm Follow-up samples may be required

Abbott Laboratories Confidential Page 5 RegionDengue*YFVTBEVMVJEVSLE Core ~ PreM/M ENV NS NS2A NS2B NS NS4A NS4B NS b * Average of Dengue type 1 through 4: analyses performed at Abbott Laboratories Amino Acid Sequence Homology Comparison of percent identity of West Nile Virus vs. Dengue, Yellow Fever, Japanese Encephalitis and St. Louis Encephalitis Viruses

Abbott Laboratories Confidential Page 6 SerumSLEJEWNDEN2YFPOW Positive Control ELISA Cross-reactivities of WNV IgM Test (S/N values as reported by CDC) * 1:400 screening dilution of WNV patient serum

Abbott Laboratories Confidential Page 7 Anti-IgM Coated Solid Phase Serum Added Diluent Antigen Added Diluent Red Conjugate Added Diluent Blue Two-Step IgM Capture EIA Timing: 1 hr/37 o C/Static 2 hr/37 o C/Static

Abbott Laboratories Confidential Page 8 West Nile Virus Studies Volunteer blood donors from 2002 Volunteer blood donors from 2002 Based on previous population studies the cut-off was provisionally set at S/N = 5.0 Experimentally infected rhesus monkeys* Experimentally infected rhesus monkeys* Daily bleeds for 2 wks Natural history of WNV *In collaboration with Dr. Tesh and associates at UTMB Galveston, TX and Dr. Marion Ratterree and associates at the Tulane National Primate Research Center, Covington, LA

Abbott Laboratories Confidential Page 9 Serologic Profile of WNV Infection in Experimentally Infected Monkeys Nested RT-PCR Virus Isolation *In collaboration with Dr. Tesh and associates at UTMB Galveston, TX and Dr. Marion Ratterree and associates at the Tulane National Primate Research Center, Covington, LA

Abbott Laboratories Confidential Page 10 Day #Virus (log)RT-PCTIgM (S/N)IgG S/NHI (titer)CF (titer)PRNT (titer) / : : :160-1: > :640-1: > :640161: > ND 1: > :128064ND :640 1: ND 1:512 Serologic Profile of Experimentally Infected Macaque #810 *In collaboration with Dr. Tesh and associates at UTMB Galveston, TX and Dr. Marion Ratterree and associates at the Tulane National Primate Research Center, Covington, LA

Abbott Laboratories Confidential Page 11 Serologic Profile of WNV Infection in Experimentally Infected Monkeys Nested RT-PCR Virus Isolation *In collaboration with Dr. Tesh and associates at UTMB Galveston, TX and Dr. Marion Ratterree and associates at the Tulane National Primate Research Center, Covington, LA

Abbott Laboratories Confidential Page 12 Day #VirusRT-PCTIgM (S/N)IgG S/NHICFPRNT : :40321: :80321: :320641: :16064ND : ND 1:1280 Serologic Profile of Experimentally Infected Macaque #J840 *In collaboration with Dr. Tesh and associates at UTMB Galveston, TX and Dr. Marion Ratterree and associates at the Tulane National Primate Research Center, Covington, LA

Abbott Laboratories Confidential Page 13 Day #Virus log PFU’s (pos/total) RT-PCR (pos/total) IgM (S/N)IgG S/NHI (titer)CF (titer)PRNT (titer) / (5/5+)5/ (3/5+)5/ (2/5+)5/ (2/5+)3/ / / / / / :20-1: :40-1: :8081: :160161: :320161: :320321: :16064ND :160161: :160161:640 Summary of Serologic Profiles of Experimentally Infected Macaques Median Values *In collaboration with Dr. Tesh and associates at UTMB Galveston, TX and Dr. Marion Ratterree and associates at the Tulane National Primate Research Center, Covington, LA

Abbott Laboratories Confidential Page 14 Experimentally Infected Macaques A total of 38 of the 41 IgM reactive specimens (S/N>5.0) were confirmed by one or more supplemental assay A total of 38 of the 41 IgM reactive specimens (S/N>5.0) were confirmed by one or more supplemental assay 2 of 5 of the first bleed dates were confirmed by one or more supplemental assays A provisional cutoff was set an S/N greater than 5.0 and utilized for human studies A provisional cutoff was set an S/N greater than 5.0 and utilized for human studies

Abbott Laboratories Confidential Page 15 IgM Detection in a Selected Population* Volunteer blood donations from 2002, from centers considered at “high risk” for WNV Infection – Dr. L Tobler Blood Centers of the Pacific; Dr. Michael Busch, America’s Blood Centers

Abbott Laboratories Confidential Page 16 NumberIgM (S/N) retest IgM 2 (S/N) PRNT Titer WNV IgG retest Supplemental Testing 1>155.5> Pos > Pos > Pos Pos Pos Pos Pos Neg0.8NDNeg* Neg1.3NDNeg* Neg1.1NDNeg* Neg0.5NDNeg* Neg.0.5NDNeg* Neg0.6NDNeg* Serologic Profile of Repeatably Reactive Human Specimens Additional supplemental testing is being performed Volunteer blood donations from 2002, from centers considered at “high risk” for WNV Infection – Dr. L Tobler Blood Centers of the Pacific; Dr. Michael Busch, America’s Blood Centers

Abbott Laboratories Confidential Page 17 SUMMARY Assay Format Finalized EIA on polystyrene beads Capture IgM completed in 3.5 hours at 37° C Preliminary evaluation of IgM testing indicates: In experimentally infected primates, IgM was detected by day 10 post infection The provisional cutoff set at S/N 5.0 appears to provide adequate specificity Specificity improvements may be made in the future if needed Research studies will continue utilizing current provisional cutoff, while evaluating supplemental testing (confirmatory) algorithms